Back to top

Analyst Blog

Regeneron Pharmaceuticals Inc. (REGN - Analyst Report) recently announced that sales of its eye drug Eylea for the final quarter of 2012 came in at $276 million. The company further announced that 2012 US sales of the drug for 2012 were $838 million. Sales of the eye-drug in 2012 were above the company’s projected range of $790-$815 million. However, the sales figures of Eylea reported by the biopharmaceutical company failed to find favor with the investors and adversely impacted the stock price. Detailed financial results for the fourth quarter and full year 2012 are expected to be announced by Regeneron shortly.

Regeneron expects sales of Eylea to increase by 50% in 2013 over 2012 levels. Consequently, 2013 sales are expected in the range of $1.2-$1.3 billion. We remind investors that Eylea was launched in the US in November 2011 for treating patients suffering from the neovascular form of age-related macular degeneration. The drug was cleared in the EU for the same indication late last year. In September 2012, the label of the drug was successfully expanded in the US to treat patients suffering from macular edema following central retinal vein occlusion (CRVO).

Partner Bayer is seeking approval of Eylea for the CRVO indication in the EU. Eylea is also being studied for other indications, such as diabetic macular edema and macular edema following branch retinal vein occlusion and myopic choroidal neovascularization.

Per the agreement, Bayer is responsible for marketing Eylea in ex-US markets on approval. The profit earned from the sales of the drug in those markets will be shared equally by the companies. However, Regeneron owns the entire US rights pertaining to the eye drug.

We have a Neutral stance on Regeneron, which carries a Zacks Rank #2 (Buy) in the short run. Biopharma stocks, which appear to be more favorably placed, include Peregrine Pharma (PPHM - Snapshot Report). The stock carries a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%